Torrent Pharmaceuticals Ltd (TORNTPHARM) Q4FY26 Concall Summary - Mar-2026 Qtr
Performance Overview
- The company reported strong consolidated revenue growth of 42% for the quarter, primarily driven by the inclusion of JB Pharma's financials from January 21, 2026.
- Torrent's base business, excluding JB Pharma, demonstrated robust organic growth with revenues and operating EBITDA both increasing by 16%, maintaining a healthy EBITDA margin of 32.7%.
- The India business continued its market-beating performance, with the base business growing at 15% against the Indian Pharmaceutical Market (IPM) growth of 10%, supported by the strong performance of the Curatio portfolio and new launches.
- International branded markets, particularly Brazil, showed healthy double-digit growth, while the US generics business also posted a solid 31% INR growth.
- The company has made significant strides in new product launches, notably becoming a market leader in generic Semaglutide in India, which is expected to be a major growth driver in the upcoming year.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.